Paclitaxel 260 mg/43.4 mL
Product Overview
| Generic Name | Paclitaxel 260 mg/43.4 mL |
| Brand Name(s) | Pacliltax, Nanoxel, Z-Taxel, Altaxel, Plaxel |
| Category | Antineoplastic / Cancer |
| Form | Injectable, multidose vial |
| Strength | 260 mg in 43.4 mL (6 mg/mL) Vial |
| Therapeutic Class | Antimicrotubule taxane agent |
| ATC Code | L01CD01 |
Manufacturing & Regulatory
| Manufacturer | Fresenius Kabi (Nanoxel), Aetos, Biogen, Cipla |
| GMP Compliance | WHO-GMP, FDA-compliant |
| DMF/CEP | Manufacturer-specific, not public |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Available from supplier on request |
Logistics & Export
| MOQ | 10 Vials |
| Shelf Life | 24 Months |
| Storage | Store = 25 °C, protect from light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 10 Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Provided with each batch |
| SDS-Safety Data Sheet (PDF) | Available from manufacturer |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
Indications & Usage: Breast, ovarian, lung, pancreatic cancers; administered IV